Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxVRCDF -60.53% Days Sales Outstanding is 116.99 as of Dec. 2025, which is 19% below its 10-year median of 144.69. The stock has 3 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Verici Dx ranks worse than 74.63% on this metric.
Verici Dx's average Accounts Receivable for the
six
months ended in Dec. 2025 was $1.12 Mil. Verici Dx's Revenue for the
six
months ended in Dec. 2025 was $1.75 Mil.
Hence, Verici Dx's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 116.99.
The historical rank and industry rank for Verici Dx's Days Sales Outstanding or its related term are showing as below:
VRCDF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 110.56 Med: 144.69 Max: 365
Current: 112.06
During the past 6 years, Verici Dx's highest Days Sales Outstanding was 365.00. The lowest was 110.56. And the median was 144.69.
VRCDF's Days Sales Outstanding is ranked worse than 74.63% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs VRCDF: 112.06
Verici Dx's Days Sales Outstanding
increased
from Dec. 2024 (0.00) to Dec. 2025 (116.99).
Verici Dx (OTCPK:VRCDF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Verici Dx Days Sales Outstanding Related Terms
Verici Dx Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Verici Dx's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRCDF vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Verici Dx's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Verici Dx's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 116.99 mean?
Verici Dx (VRCDF) has a Days Sales Outstanding of 116.99 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Verici Dx and its competitors. This is 19% below median its historical median of 144.69. Over the past decade, Verici Dx's Days Sales Outstanding has ranged from 110.56 to 365.00. According to the industry distribution chart, Verici Dx ranks #150 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 74.6%.
Is Verici Dx's Days Sales Outstanding too high?
Verici Dx's current Days Sales Outstanding of 116.99 is 19% below median its 10-year median of 144.69. Over the past 10 years, this metric has ranged from a low of 110.56 to a high of 365.00. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Verici Dx's value of 116.99 is 73.1% above this industry median. Based on the distribution chart, Verici Dx ranks #150 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Verici Dx's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #150 out of 201 companies for Days Sales Outstanding. This places Verici Dx in the lower half of its industry. The industry median Days Sales Outstanding is 67.59. Verici Dx's value of 116.99 is 73.1% above this benchmark. Historically, Verici Dx's own Days Sales Outstanding has ranged from 110.56 to 365.00 over the past decade. While the company's 10-year median is 144.69 vs. the industry median of 67.59, Verici Dx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verici Dx's current Days Sales Outstanding of 116.99 is 73.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Verici Dx and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verici Dx's current Days Sales Outstanding is 116.99, which is 19% below median its own 10-year median of 144.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (VRCDF) has a current Days Sales Outstanding of 116.99. The current Days Sales Outstanding is 116.99, which is 19% below median its 10-year median of 144.69 and 73.1% above the Medical Diagnostics & Research industry median of 67.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Verici Dx (VRCDF), the current Days Sales Outstanding is 116.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRCDF has been successfully added to your 
